Navigation Links
HYALGAN® (sodium hyaluronate) Commercial Rights Transfer Back to Fidia Farmaceutici S.p.A.

PARSIPPANY, N.J., Sept. 15, 2011 /PRNewswire/ -- Fidia Farmaceutici S.p.A. (Fidia) announced today that commercial rights for HYALGAN ® (sodium hyaluronate), an injectable treatment for knee pain caused by osteoarthritis when simple painkillers or exercise and physical therapy are not enough, will be transferred from Sanofi US LLC back to Fidia on September 24, 2011.  Fidia Farmaceutici S.p.A. is the owner and manufacturer of HYALGAN. After September 24th, Fidia will promote, distribute and sell HYALGAN in the United States through its wholly owned subsidiary, Fidia Pharma USA Inc, headquartered in Parsippany, N.J.

The company stated that the transfer of US commercial responsibility for HYALGAN will not result in any change to the product. Current volume purchase agreements will continue to be honored and the product's current J-code will remain unchanged.  Critical services such as the HYALGAN® patient assistance program will also remain unchanged and can be accessed at 1-866-7-HYALGAN. Until September 24th, medical professionals can direct their questions about HYALGAN to their Sanofi US LLC sales representative.

HYALGAN was approved for marketing by the U.S. Food and Drug Administration in 1997.  More than 38 million doses of HYALGAN® have been administered worldwide since its introduction.(1)

About Fidia Farmaceutici S.p.A

Headquartered in Abano Terme, Northeast Italy, Fidia Farmaceutici S.p.A., has over 50 years of successful R&D and industry experience with biologically active molecules.  As a model for international success, Fidia has focused its core business activities on hyaluronic acid, developing and providing a wide range of products for various specialties. Fidia holds more than 960 patents on hyaluronic acid and its applications and its products are currently in over 70 countries worldwide.  Fidia's most important proprietary platform technology at a worldwide level is the chemical modification, development, and manufacturing of state-of-the-art pharmaceuticals and medical devices based on hyaluronan covering multiple therapeutic categories including joint care, advanced wound care, and aesthetic medicine.

Helping people stay healthy is Fidia's corporate commitment.  For more information, visit

(1)  Data on File, Fidia Farmaceutici S.p.A.
BP.F.H.035  911

SOURCE Fidia Farmaceutici S.p.A.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
2. Jazz Pharmaceuticals Announces FDA Acceptance of its New Drug Application for JZP-6 (sodium oxybate) for the Treatment of Fibromyalgia
3. Jazz Pharmaceuticals Provides Update on FDA Advisory Committee Meeting For JZP-6 (Sodium Oxybate) in Fibromyalgia
4. Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
5. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
8. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
9. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
10. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
11. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 AAIPharma Services ... investment of at least $15.8  Million to expand ... Wilmington, NC . The expansion will provide ... meet the growing demands of the pharmaceutical and ... site expansion will provide up to 40,000 square ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ) today announced that ... York State Attorney General,s Office to end the ... statutes with the Attorney General over the decision of Forest ... selling the now generic version of memantine immediate release tablets.  ... released its counterclaims against New York , ...
(Date:11/25/2015)... 25, 2015 USP 800 applies to ... (e.g. pharmacists, pharmacy technicians, nurses, physicians, physician assistants, ... chapter also covers all entities which store, prepare, ... other healthcare institutions, patient treatment clinics, physicians, practice ... --> What is the purpose ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... 25, 2015 , ... According to an article published November 10th ... widely heralded as a breakthrough for performing hernia repairs. The article explains that the ... is that it can greatly reduce the pain that a patient might otherwise experience ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug ... a new cutting edge recovery program that has been 50 years in the making. ... individuals with the purpose to free addicts from the symptoms and negative behaviors of ...
(Date:11/25/2015)... ... , ... On November 23rd 2015 Cozy Products, a division of ... Cozy Products explains what this means for business moving forward. , The Tri Lite ... business model: to sell personal heaters that reduce energy consumption, are economical and keep ...
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a new ... systems. The new app features a more intuitive SleepScore™ that rates sleep quality on ... slept. The SleepScore is created by a proprietary algorithm. Beddit analyzes the data to ...
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, ... from Bronx, N.Y. “I thought there had to be a convenient and comfortable way ... , The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. ...
Breaking Medicine News(10 mins):